Name : Cynomolgus PCSK9 Protein
Product Source :
Recombinant Cynomolgus PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Glu151-Gln811.[Accession | A0A2K5TZC4]
Molecular Weight :
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus PCSK9 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Cynomolgus PCSK9 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Cynomolgus PCSK9, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve Anti-PCSK9 Antibody, hFc Tag with the EC50 of 81.5ng/ml determined by ELISA (QC Test). SPR Data Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind Cynomolgus PCSK9, His Tag with an affinity constant of 0.27 nM as determined in SPR assay (Biacore T200).
Background :
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Synonyms :
PCSK9
References & Citations :
(1)McKenney, James M. Understanding PCSK9 and anti-PCSK9 therapies[J]. Journal of Clinical Lipidology, 2015, 9(2):170-186.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
HTRA2/OMI Protein
GLP1R Protein
Popular categories:
Siglec-7
DNAM-1/CD226